Scott Matusow | TalkMarkets | Page 1
StockMatusow.com
Contributor's Links: StocksNSox
Writers here are Scott Matusow and Dan Cohen Scott is an independent investor/writer/trader and team leader of StockMatusow.com. He has over 25 years of stock market experience which include trading futures, options, and stock markets. Scott has had the most success in trading/investing in smaller ...more

All Contributions

Latest Posts
1 to 16 of 30 Posts
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope with Hematopoietic Stem Cell Transplantation.
GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow
Dan Cohen and Scott Matusow discuss In this 1:11 audio the upcoming data sets for Glycomimetics. We talk about The Company's platform chemistry in depth, and give our predictions for success/failure of said data.
A Perspective On The Upcoming Calithera Cystic Fibrosis Read-Out
Calithera is guiding for the market to expect what we believe will be a key data read-out in Q3 from its ongoing CB-280 study involving Cystic Fibrosis. A positive read-out here could see a significant upside for the company stock.
Calithera Biosciences: An Under The Radar Opportunity
Calithera is a high-risk, high reward speculative investment addressing high unmet and under-served needs markets, with a lower bar data threshold to meet. Calithera has an important near-term catalyst shortly upcoming.
An Activist Fund Has Been Buying This Biotech
When a fund files a 13D, it indicates that it intends to be an activist investor. Activist investors often facilitate new business paths, partnerships, and acquisitions.
2 Names To Consider In A Heating Up Small-Cap Biotech Sector
The biotech sector has been heating up due to an increased risk appetite coming from additional market liquidity and a favorable Fed policy. Here, we highlight 2 early-stage biotech companies that we think can provide substantial upside.
3 Small Cap Biotechs With Upcoming Catalysts
Catalyst Trading in biotech stocks can be very profitable. Often times, many catalyst events are over looked by the market, especially when it comes to small cap biotech.
3 Biotechs With Upcoming Data To Be Presented At Conferences
Biotech stocks tend to have strong movement when their respective companies have binary events upcoming in short order. Here are 3 companies with upcoming data to be presented at data conferences this week.
4 Small Cap Biotechs With Upcoming Catalysts
The biotech “run-up” trade has always attracted a wide array of traders looking to take advantage of potentially high alpha price moves before the actual catalyst/binary event come to fruition.
MyoKardia Brings Hope To Hypertrophic Cardiomyopathy Patients
Obstructive Hypertrophic Cardiomyopathy affects roughly 1 out of 500 persons in the U.S, and globally. MyoKardia based on my research has a good chance to successfully treat this highly underserved and unmet need patient population.
GlycoMimetics - High Potential Clinical-Stage Biotech
GlycoMimetics is a clinical-stage biotech that we feel has significant potential to be a short, mid, and long term winner. The company has a unique and novel platform in which early data looks very promising.
Calithera Pharma In Focus, Part 3 - Arginase Inhibitor And Acquisition Target
In the last part of our series on Calithera Biosciences we will be examining the company's second clinical asset and its acquisition chances sometime this year or early 2018.
Calithera In Focus, Part 2 - Upcoming Catalysts In TNBC And RCC
In this article, we will review Calithera's upcoming data catalyst value drivers, which should positively effect the company's market capitalization moving forward. Calithera is also poised to eventually become a high value acquisition.
Calithera Pharma In Focus, Part 1 - Checkpoint Inhibition
Clinical stage company Calithera presents an early stage investment opportunity with the ability to enhance therapeutic value to the first wave of IO therapeutics checkpoint inhibitors from Merck's Keytruda and Bristol-Myers Squibb's Opdivo.
Negative Interest Rates Next Up - Will Pump Markets But Eventually Destroy The Global Financial System
In this article, I will go over several key factors concerning future negative interest rates, Quantitative Easing (QE), leverage and liquidity, economic growth and the lack thereof, debt, and my forecast on what to expect moving forward from here.
1 to 16 of 30 Posts